Trial Profile

A Phase 1/2, Multicenter, Double-Masked, Placebo-Controlled Study of KB801 in Subjects With Stage 2 or 3 Neurotrophic Keratitis

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KB 801 (Primary)
Indications Neurotrophic keratopathy
Focus Adverse reactions
Acronyms EMERALD-1
Sponsors Krystal Biotech

Most Recent Events

31 May 2025 Status changed from planning to recruiting.
13 May 2025 New trial record
06 May 2025 According to a Krystal Biotech media release, the Company expects to dose the first patient in EMERALD-1 study, later this month.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com